Search Results

Mainz Biomed NV, a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce the addition of Bioclinica to its esteemed network of laboratory partners.

Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the live launch of Mainz Biomed’s flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test for colorectal cancer (CRC) - with strategic partner Bioclinica, a national leader in the Romanian healthcare sector.

Bioclinica, an ERT company, today announced receiving 2021 CRO Leadership Awards for four consecutive years in multiple performance categories.

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today launched Source Document Manager

New AI integration dramatically speeds medical image interpretation and model creation within Bioclinica’s imaging platform

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, today announced the addition of eTMF as part of its CTMS offering.

Bioclinica, an ERT company, announced the addition of eConsent as part of its Electronic Data Capture and Management suite of products.

Bioclinica, a leading provider of clinical science and technology expertise to assist the life science industry, today announces that David Herron, Bioclinica’s President and Chief Executive Officer, will be leaving the company to pursue other business interests.